Phase 3 Type 1 Diabetes Trial, Recruiting (NCT07564414)

Phase 3 Type 1 Diabetes Trial, Recruiting NCT07564414 Sponsor: Novo Nordisk A/S Condition: Type 1 Diabetes

Printed from Voxsanity (voxsanity.com.au) — NCT07564414 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Type 1 Diabetes

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Anyone aged 18 or older, of any gender identity, regardless of sex assigned at birth
People with a Body Mass Index (BMI) of 35 or higher (a measure of body weight relative to height)
People without type 2 diabetes, meaning they have no history of it and a blood sugar (HbA1c) reading below 6.5%
People with type 2 diabetes, meaning they have a confirmed history of it and a blood sugar (HbA1c) reading below 10%
Note: if your blood sugar reading comes back at 6.5% or higher during initial checks and you have no history of diabetes, a doctor must confirm a type 2 diabetes diagnosis before you can join (confirm with trial site)

Who may not be able to join:

People whose body weight has changed by more than 5% in the 90 days before joining the trial, based on their own account
People who have used certain diabetes or weight-related medications — specifically GLP-1 receptor agonists (such as semaglutide or liraglutide) or amylin analogues — within the 6 months before joining the trial (confirm with trial site if unsure whether your medication falls into these categories)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 16 July 2026

Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Phone: (+1) 866-867-7178

Australian sites

Sydney Clinical Trials, Campbelltown, New South Wales

Gosford Renal Research, Gosford, New South Wales

Sydney Cardiometabolic Centre, Liverpool, New South Wales

Hunter Diabetes Centre, Merewether, New South Wales

University of Sunshine Coast - Vitality Village, Birtinya, Queensland

University of Sunshine Coast - South Brisbane, South Brisbane, Queensland

Emeritus Research Melbourne, Camberwell, Victoria

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07564414

Sponsor: Novo Nordisk A/S

Phase: Phase 3

Status: Recruiting

Condition: Type 1 Diabetes

Trial contact: (+1) 866-867-7178

More information: https://clinicaltrials.gov/study/NCT07564414

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Anyone aged 18 or older, of any gender identity, regardless of sex assigned at birth
People with a Body Mass Index (BMI) of 35 or higher (a measure of body weight relative to height)
People without type 2 diabetes, meaning they have no history of it and a blood sugar (HbA1c) reading below 6.5%
People with type 2 diabetes, meaning they have a confirmed history of it and a blood sugar (HbA1c) reading below 10%
Note: if your blood sugar reading comes back at 6.5% or higher during initial checks and you have no history of diabetes, a doctor must confirm a type 2 diabetes diagnosis before you can join (confirm with trial site)

Who may not be able to join:

People whose body weight has changed by more than 5% in the 90 days before joining the trial, based on their own account
People who have used certain diabetes or weight-related medications — specifically GLP-1 receptor agonists (such as semaglutide or liraglutide) or amylin analogues — within the 6 months before joining the trial (confirm with trial site if unsure whether your medication falls into these categories)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 16 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 3

Sponsor

Novo Nordisk A/S

Registry

ClinicalTrials.gov

Start date

21 May 2026

Est. completion

23 February 2028

Where this trial is recruiting

🇦🇷 Argentina 🇦🇺 Australia 🇦🇹 Austria 🇧🇪 Belgium 🇧🇬 Bulgaria 🇨🇦 Canada 🇨🇿 Czechia 🇫🇷 France 🇬🇷 Greece 🇭🇺 Hungary 🇮🇹 Italy 🇳🇱 Netherlands 🇵🇱 Poland 🇵🇹 Portugal 🇷🇴 Romania 🇸🇰 Slovakia 🇿🇦 South Africa 🇪🇸 Spain 🇺🇸 United States

7 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Relative change in body weight

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov